HTG Molecular Diagnostics Completes Initial Technical Feasibility Testing with QIAGEN GeneReader NGS System
March 23 2017 - 4:01PM
HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM) (“HTG”), a provider
of instruments, reagents, and services for molecular profiling
applications, today announced that its HTG EdgeSeq technology
has been successfully adapted for use with the QIAGEN GeneReader
NGS System based on the results of initial technical feasibility
tests. Results from samples tested with the HTG EdgeSeq DLBCL
Cell of Origin Assay gene panel adapted for detection with the
GeneReader NGS System showed strong correlation
(r = 0.98) to data previously generated on the MiSeq
sequencer.
“We are pleased to show the feasibility of using our
HTG EdgeSeq technology with the GeneReader NGS System, which
will expand the sequencing platforms available for use with our
system, and, importantly, advances our precision diagnostics
collaboration with QIAGEN. The HTG and QIAGEN teams have been
working very closely and we are delighted with their speed and
efficiency to accomplish this initial feasibility milestone,”
stated TJ Johnson, Chief Executive Officer of HTG.
“Adapting our HTG EdgeSeq technology for detection on the
GeneReader NGS System has been fairly straightforward to date and
the initial testing results were gratifying,” said Debrah Thompson,
Ph.D., HTG’s Vice President of Research. “The level of cooperation
between the QIAGEN and HTG technical teams has been outstanding,
and we are excited about the future of this collaboration.”
About HTG:
Headquartered in Tucson, Arizona, HTG’s mission is to empower
precision medicine at the local level. In 2013, the company
commercialized its first instrument platform and a portfolio of RNA
assays that leveraged HTG's original proprietary nuclease
protection chemistry. Continuous improvement led to the 2014 launch
of the company’s HTG EdgeSeq product line, which automates sample
and targeted library preparation for next-generation sequencing.
Additional information is available at www.htgmolecular.com.
Safe Harbor Statement:
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995, including statements associated with the results of
initial feasibility testing using the GeneReader platform and our
agreement and collaboration with QIAGEN Manchester Limited, a
wholly owned subsidiary of QIAGEN, N.V. (“QIAGEN”) and their
expected benefits to us, and our business and the capabilities of
our technology. Words such as "believes," "anticipates," "plans,"
"expects," "intends," "will," "goal," "potential" and similar
expressions are intended to identify forward-looking statements,
though not all forward-looking statements necessarily contain these
identifying words. These forward-looking statements are based upon
management's current expectations, are subject to known and unknown
risks, and involve assumptions that may never materialize or may
prove to be incorrect. Actual results and the timing of events
could differ materially from those anticipated in such
forward-looking statements as a result of various risks and
uncertainties, including, without limitation, risks associated with
our ability to successfully develop, market and/or commercialize
new methods, technologies and/or products, including our ability to
further adapt our technology to the GeneReader NGS System and
expand the sequencing platforms available for use with our HTG
EdgeSeq system, or successfully develop and commercialize any
related products or services. These and other factors are described
in greater detail in our filings with the Securities and Exchange
Commission, including without limitation our Annual Report on Form
10-K for the year ended December 31, 2016. All forward-looking
statements contained in this press release speak only as of the
date on which they were made, and we undertake no obligation to
update such statements to reflect events that occur or
circumstances that exist after the date on which they were
made.
Contact:
Westwicke Partners
Jamar Ismail
Phone: 415-513-1282
Email: jamar.ismail@westwicke.com
TJ Johnson
President / CEO
HTG Molecular Diagnostics
Phone: 520-547-2827 x130
Email: tjjohnson@htgmolecular.com
HTG Molecular Diagnostics (NASDAQ:HTGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
HTG Molecular Diagnostics (NASDAQ:HTGM)
Historical Stock Chart
From Apr 2023 to Apr 2024